Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
Lupin appoints Brian Savage as President and Chief Legal Officer
Savage will lead Lupin’s global Legal, Compliance and Intellectual Property Management Group functions and will be based in New Jersey The post Lupin appoints Brian Savage as President and Chief Legal Officer appeared first on Express Pharma.
Read Full Article
Pharma Tech
CPHI 2026: Pharma manufacturers put AI to work
At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.
Read Full Article
Pharma Tech
Roche’s pharma sales grow 7% but pipeline trimmed down
Several drugs fuelled Roche’s sales for the first nine months reflecting the company’s diverse commercial portfolio.
Read Full Article
Pharma Tech
Danish fast-track model inspires growth in national reimbursement rates
As of 1 June 2026, a novel assessment process for PD-(L)1 drugs was implemented in Denmark by the Danish Medicines Council.
Read Full Article
Pharma Tech
Retatrutide peptide: A quality-control checklist for sourcing research-grade material
Explore retatrutide peptide quality control, including batch testing and supplier documentation checks for laboratory research.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 23, 2026, 6:30 AM
Merck and Moderna Report P-III (INTerpath-001) Trial Data of Intismeran Autogene + Keytruda for Resected Melanoma at ESMO 2026
Shots: Merck & Moderna have reported detailed data from the P-III (INTerpath-001) trial evaluating intismeran autogene + Keytruda vs Keytruda alone as adjuvant treatment in 1,137 pts with completely resected stage IIB-IV melanoma; data will be presented at ESMO 2026 (#LBA1) & accepted for publication in NEJM At a median follow-up of 24.6mos, the combination… The post Merck and Moderna Report P-III (INTerpath-001) Trial Data of Intismeran Autogene + Keytruda for Resected Melanoma at ESMO 2026 appeared first on PharmaShots.
ET Pharma
Oct 23, 2026, 5:58 AM
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal
The deal follows positive mid-stage results for Gilead's experimental pill for chronic bowel disease, emvistegrast, on Monday and adds the new inflammatory bowel disease candidate to its portfolio.
Express Pharma
Oct 23, 2026, 5:41 AM
Lupin appoints Brian Savage as President and Chief Legal Officer
Savage will lead Lupin’s global Legal, Compliance and Intellectual Property Management Group functions and will be based in New Jersey The post Lupin appoints Brian Savage as President and Chief Legal Officer appeared first on Express Pharma.
PharmaShots
Oct 23, 2026, 5:30 AM
BioNTech Collaborates with Gilead to Evaluate Pumitamig + Trodelvy (Sacituzumab Govitecan) in P-III (ROSETTA Breast-01) Trial for Triple-Negative Breast Cancer
Shots: BioNTech has entered into a clinical trial collaboration & supply agreement with Gilead to evaluate pumitamig + sacituzumab govitecan (Trodelvy), a TROP2-directed ADC, as 1L treatment of locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (TNBC); pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, is being jointly developed by BioNTech & BMS The global,… The post BioNTech Collaborates with Gilead to Evaluate Pumitamig + Trodelvy (Sacituzumab Govitecan) in P-III (ROSETTA Breast-01) Trial for Triple-Negative Breast Cancer appeared first on PharmaShots.
PharmaShots
Oct 23, 2026, 4:30 AM
AbbVie Reports Topline P-III (INTREPID) Trial Results of Lutikizumab for Hidradenitis Suppurativa (HS)
Shots: AbbVie has reported topline results from the P-III (INTREPID) study evaluating lutikizumab, an investigational dual-variable-domain IL-1α/1β antagonist, in adults & adolescents with moderate to severe hidradenitis suppurativa (HS); 1,400 pts were randomized (1:1) to lutikizumab SC or PBO, & the study met its 1EP & 8 ranked 2EPs Lutikizumab achieved HiSCR75 at Wk16 (31.4%… The post AbbVie Reports Topline P-III (INTREPID) Trial Results of Lutikizumab for Hidradenitis Suppurativa (HS) appeared first on PharmaShots.
ET Pharma
Oct 23, 2026, 2:29 AM
UNICEF and Gavi agree to cut Mosquirix malaria vaccine price by 40%
The deal, executed by UNICEF and financially backed by Gavi, is expected to generate around $50 million in savings between 2027 and 2029 and will bring the price of the vaccine down to €5.50 ($6.16) per dose
News
Latest industry coverage
Google News
Oct 23, 2026, 6:34 AM
Messe Muenchen India Acquires PharmaTech Expo to Expand Its Pharmaceutical Industry Portfolio - Chemical Industry Digest
Messe Muenchen India Acquires PharmaTech Expo to Expand Its Pharmaceutical Industry Portfolio Chemical Industry Digest
Google News
Oct 23, 2026, 6:23 AM
Research prompts call to tackle pharmaceutical industry promotion as a commercial determinant of health - Croakey Health Media
Research prompts call to tackle pharmaceutical industry promotion as a commercial determinant of health Croakey Health Media
Google News
Oct 23, 2026, 5:19 AM
Lupin Appoints Brian Savage as President, Chief Legal Officer - Lupin | Press Release - Lupin
Lupin Appoints Brian Savage as President, Chief Legal Officer - Lupin | Press Release Lupin
Google News
Oct 23, 2026, 4:29 AM
Afghan trade halt hits Pakistan’s pharma exports - Asia News Network
Afghan trade halt hits Pakistan’s pharma exports Asia News Network
Google News
Oct 23, 2026, 4:03 AM
Piyush Goyal holds talks with Fresenius, Bayer, Knauf executives to explore deeper India collaboration - First India
Piyush Goyal holds talks with Fresenius, Bayer, Knauf executives to explore deeper India collaboration First India
Google News
Oct 23, 2026, 3:43 AM
US to restrict investments in Chinese biotech firms - The Standard (HK)
US to restrict investments in Chinese biotech firms The Standard (HK)
Google News
Oct 23, 2026, 3:36 AM
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals - Fierce Biotech
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals Fierce Biotech
Google News
Oct 23, 2026, 3:10 AM
US Proposes Curbs on Investment in Chinese Biotech Firms - Bloomberg.com
US Proposes Curbs on Investment in Chinese Biotech Firms Bloomberg.com
Google News
Oct 23, 2026, 3:08 AM
Eli Lilly, state officials break ground on $5 billion facility that will make ‘medicines of the future’ - WRIC ABC 8News
Eli Lilly, state officials break ground on $5 billion facility that will make ‘medicines of the future’ WRIC ABC 8News
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer